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Abstract
We have previously shown that plasmablasts of the G1m1 allotype of IgG1 are
selectively enriched in the cerebrospinal fluid of G1m1/G1m3 heterozygous
patients with multiple sclerosis, whereas both allotypes are equally used in neu-
roborreliosis. Here, we demonstrate a strong preference for the G1m1 allotype
in the intrathecal humoral immune responses against measles, rubella, and vari-
cella zoster virus in G1m1/G1m3 heterozygous multiple sclerosis patients. Con-
versely, intrathecally synthesized varicella zoster virus-specific IgG1 in varicella
zoster virus meningoencephalitis comprised both allotypes. This implies that
G1m1 B cells are selected to the central nervous system of multiple sclerosis
patients regardless of specificity and suggests that an antigen-independent
mechanism could drive the intrathecal humoral immune response.
Introduction
The efficacy of anti-CD20 therapy in multiple sclerosis
(MS) has put B cells in the spotlight for their pathogenic
involvement.1 B cells can present antigens to T cells,
undergo affinity maturation and clonal expansion, and
differentiate into antibody-secreting cells.2 In a majority
of MS patients, antibody-secreting cells are present in the
central nervous system, and locally produced
immunoglobulin G (IgG) can be detected in the cere-
brospinal fluid (CSF) as oligoclonal bands (OCB).3 Curi-
ously, an intrathecal humoral immune response targeting
commonly encountered viruses, including measles,
rubella, and varicella zoster virus (VZV) can be observed
in most MS patients, as opposed to patients with other
neuroinflammatory diseases.4–8 These antibodies consti-
tute a minor fraction of the intrathecally synthesized
antibodies and are believed to be irrelevant to the
pathophysiology of MS.7 In contrast, no consensus has
been found regarding an MS-specific target of the major
oligoclonal IgG fractions.
It has been shown that genetic variants in the IGHG1
gene on chromosome 14 coding for the G1m allotypes
on the IgG1 constant chain influence IgG levels in the
CSF and MS risk.9–11 We recently demonstrated a domi-
nance of plasmablasts carrying the G1m1 allotype in the
CSF of G1m1/G1m3 heterozygous MS patients, as
opposed to patients with neuroborreliosis.12 However,
the mechanism driving the G1m1 bias is not clear, and
proposes a closer look to antigen specificity as a poten-
tial influencing factor. GM genes have previously been
shown to regulate the magnitude of IgG responses to
cytomegalovirus, and G1m allotypes have demonstrated
differential binding to several viral Fc receptors.13,14 To
address whether the selection of G1m1 plasmablasts is
influenced by antigen specificity, we here examined the
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Thirty paired CSF and serum samples of G1m1/G1m3
heterozygous, OCB positive, relapsing-remitting MS
patients were collected from the Departments of Neurol-
ogy at Akershus University Hospital, Oslo University
Hospital and the Norwegian MS Registry and Biobank at
Haukeland University Hospital, of which 28 patients had
been included in our previous study.12 Twenty-eight of
the patients were recruited as they underwent lumbar
puncture for diagnostic purposes, and two patients were
included solely for research. All patients met the 2010
McDonald criteria for MS diagnosis, and 7 patients had
clinical evidence of an acute relapse within 2 weeks before
lumbar puncture. Paired CSF and serum samples of 10
G1m1/G1m3 heterozygous VZV meningoencephalitis
patients were collected from the diagnostic biobanks of
Oslo University Hospital and Akershus University Hospi-
tal and used as controls. The controls tested positive for
PCR against VZV in the CSF, had increased mononuclear
CSF cell count, and symptoms compatible with VZV
meningoencephalitis. G1m allotypes were determined in
MS patients and controls using ELISA as previously
described.12 Two MS samples were considered unsuitable
for analysis, due to degradation. Approvals were issued by
The Regional Ethical Committee South East (2009/23 S-
04143a), and the Regional Ethical Committee West
(046.03/2010.1821). We obtained written informed con-
sent from all participants before inclusion.
Isoelectric focusing and affinity blotting
Viral antigens validated and approved for diagnostic use
(Serion) of Measles (Strain Edmonston, Vero cell cul-
ture), VZV (Strain Ellen, HEL-299 cell culture) or Rubella
(Strain HPV-77, Vero cell culture) were diluted to 10 lg/
mL and used for overnight incubation of nitrocellulose
paper (NCP; Amersham Protran Premium 0.45 lm NC;
GE Healthcare). Control antigens (Serion) comprised the
cell cultures used to obtain viral antigens (Vero and HEL-
299 cell cultures, Serion).
We concentrated CSF samples (Vivaspin 500; Sartorius)
and normalized CSF and serum IgG concentrations to
100 mg/L. Four microliter of paired samples were loaded
on Isogel Agarose IEF Plate pH 3-10 (Lonza), and focused
on a Multiphor II Electrophoresis System (GE Health-
care).12 After incubating the antigen-coated NCP in 4%
ECL Advance Blocking Agent (Amersham) for 50 min,
we blotted it against the focused gel for 45 min. Next, the
NCP was incubated overnight in mouse anti-human anti-
bodies against IgG1 (1.0 lg/mL, HP6069, Invitrogen,
Molecular Probes), G1m1 (31 ng/mL, 10H1), or G1m3
(0.20 lg/mL, HP6027, Abingdon Health). Controls for
each antigen were selected from CSF of G1m1 and G1m3
homozygous MS patients. For visualization, we incubated
the NCP in HRP-conjugated goat anti-mouse IgG anti-
bodies (Southern Biotec) for 1 h and further applied
SuperSignal West Pico (Thermo Fisher Scientific) accord-
ing to manufacturer instructions. We exposed the NCP
for 1 h in a G:BOX digital camera system (Syngene), and
collected multiple images at different exposure times.
Two investigators analyzed the results independently,
and there were no disagreements between the individual
assessments. Intrathecal synthesis was defined as at least
one band or distinct area exclusive to CSF or at least two
times stronger than corresponding bands in serum.
Determining virus-specific humoral immune
responses using ELISA
IgG1 concentrations were determined in all samples
using the IgG1 Human ELISA Kit (Thermo Fisher Scien-
tific) according to manufacturer instructions. We diluted
all CSF and serum samples to 1 lg/mL IgG1 in PBS
with 1% BSA and incubated paired duplicates of 50 lL
for 120 min on ELISA plates coated with measles virus,
VZV, or rubella virus antigens (Serion). After washing
with TPBS, the samples were stained with mouse-anti
human G1m1 (1.5 lg/ml, 10H1) or G1m3 (1.0 lg/mL,
HP6027) and incubated for 90 min. The plates were
washed again and incubated with rabbit anti-mouse IgG
secondary antibodies conjugated with alkaline phos-
phatase (SuperClonal antibodies, A27032; Thermo Fisher
Scientific). The signal was visualized with phosphatase
substrate (Sigma-Aldrich) reactivity measured at 405 nm.
Appropriate positive and negative control sera were
included on all plates. The negative control sera con-
sisted of sera from individuals not immunized with the
relevant viruses (sera from non-vaccinated, non-patho-
gen exposed individuals). The optical density from the
wells incubated with the negative serum (always < 0.1)
was subtracted from readings on the same plate. To gen-
erate standard curves, we coated plates (Nunc, 436014;
Thermo Fisher Scientific) with G1m1 or G1m3 myelo-
mas in two-fold dilutions and processed them in parallel
with the virus-coated plates using the same reagents.
The readout for the standard curves was ng/ml, but
since antibody activity cannot be assayed in concentra-
tion, we converted to arbitrary units (AU)/mL, where
1 AU/mL is analogous to 1 ng/mL.
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Validation of antibody specificities
To validate the anti-G1m1 and the anti-G1m3 antibodies,
we included an additional 16 individuals (10 MS patients
and 6 patients with other inflammatory neurological dis-
eases). From these individuals, IgG had previously been
isolated and subjected to trypsin cleavage and mass spec-
trometry as described elsewhere.15 In order to identify the
two CH3 allotype sequences in the mass spectrometry
raw data, we used MaxQuant software16 with a database
containing the CH3 sequences of both IgG1 allotypes.
ELISA was used to determine the antibody reactivities
against IgG in serum,12 and the results were compared to
the mass spectrometry data from trypsinized IgG from
the same individuals. This revealed a 100% match
between the antibody reactivities and the mass spectrome-
try data (P < 0.0001, binomial test, Table S1 and Fig. S1),
confirming the antibody specificities.
Data analysis
Statistical tests are named in the figure legends. Tests were
two-tailed, with the significance level set at 5%. GraphPad
Prism 7 was used for analysis.
Results
To identify patients with intrathecal anti-viral humoral
immune responses, we screened paired CSF and serum
samples from 30 G1m1/G1m3 heterozygous OCB positive
relapsing-remitting MS patients using isoelectric focusing
and affinity blotting (representative blots are shown in
Fig. S2A). Patients’ characteristics are given in Table 1.
Intrathecal synthesis of IgG1 against measles, rubella, or
VZV was detected in 25/30 patients (83%) (Fig. S2B).
Individually, there were positive findings against measles
in 16/30 (53%), against VZV in 15/30 (50%) and against
rubella in 16/30 (53%) patients. 17/30 (57%) demon-
strated intrathecal antibody synthesis against at least two
viral antigens, while 5/30 (17%) patients produced IgG1
specific to all three (Fig. S2B). All samples proved nega-
tive when blotted against control antigens. Similarly,
paired CSF and serum samples from 10 controls with
VZV meningoencephalitis were screened for intrathecal
synthesis of IgG1 against VZV (Fig. S2C). We found 6/10
(60%) controls to have intrathecal production against
VZV. When assessing the presence of bands, we analyzed
multiple exposure times, to ensure identifying antibodies
found in lower concentrations, depicted through weaker
signal (Fig S3).
Next, we used isoelectric focusing and affinity blotting
to determine the G1m allotypes of the virus-specific IgG1
OCB in MS patients and controls with VZV meningoen-
cephalitis (Fig. 1A and B). In the vast majority of MS
patients, we found a predominant usage of the G1m1
allotype in intrathecally synthesized antibodies against all
tested viruses (Fig. 1B). We detected five exceptions, of
which three against measles and two against rubella. In all
exceptions, G1m3 antibodies were always accompanied by
G1m1. In the six controls with VZV meningoencephalitis
displaying an intrathecal IgG1 synthesis against VZV, we
found that the G1m1 and G1m3 allotypes were equally
present (Fig. 1A and B).
To quantify the anti-viral antibodies of both G1m allo-
types, we used ELISA to analyze paired CSF and serum
samples from the patients shown to display intrathecal
anti-viral IgG1 synthesis (Fig. 2A). Anti-viral G1m1 levels
were significantly higher in CSF compared to serum for
all viruses tested, while G1m3 antibodies were signifi-
cantly higher in the CSF compared to serum for measles
virus, but not for rubella or VZV. When assessing the
CSF:serum ratios of anti-viral antibodies, the ratio for
G1m1 antibodies was significantly higher than that for
G1m3 in all investigated viruses (Fig. 2A). In contrast,
when quantifying the G1m allotypes of VZV-specific IgG1
in controls with VZV meningoencephalitis, we observed
higher levels of both allotypes in the CSF from 6 of 10
controls (Fig. 2B), but the CSF:serum ratio of anti-VZV
IgG1 were similar for the G1m1 and G1m3 allotypes
(Fig. 2B). The G1m1:G1m3 ratio indicated an unequivo-
cal increase in CSF of MS patients compared to serum, as
well as compared to the CSF and serum of controls with
VZV meningoencephalitis (Fig. 2C).
Discussion
The mechanism driving the selection of G1m1 positive
plasmablasts to the CSF in MS is not known. It has been
Table 1. Demographic and clinical data of all study participants.
RRMS patients
(n = 30)
Mean age in years (range; SD) 40 (18–63; 10)
Female/Male 17/13
Mean disease duration in months (range; SD) 84 (0–356; 95)1
EDSS (range; SD) 2 (0–6;1.4)2
Mean number of relapses (range; SD) 2 (1–5; 1)2
Mean duration since last relapse in months
(range)
12.2 (0–148)2
Patients undergoing DMT at CSF collection 3/30 (10%)
RRMS, relapsing-remitting multiple sclerosis; SD, standard deviation;
EDSS, Expanded Disability Status Scale; DMT, disease modifying treat-
ment.
1Missing data from one patient
2Missing data from two patients.
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Figure 1. Intrathecal synthesis of IgG1 against measles, rubella and varicella zoster virus (VZV) shows G1m1 allotype predominance in MS
patients and an even distribution in controls with VZV meningoencephalitis (VZV-ME). (A) The three upper panels show representative isoelectric
focusing and affinity blotting against measles, rubella and VZV, determining IgG1 synthesis of G1m1 and G1m3 allotypes in three G1m1/G1m3
heterozygous MS patients. CSF samples from homozygous MS patients with virus-specific intrathecal synthesis were used as positive and negative
controls. The bottom panel shows the results from three representative controls with VZV-ME after affinity blotting against VZV. (B) Isoelectric
focusing and affinity blotting was performed on paired CSF and serum samples of G1m1/G1m3 heterozygous MS patients to determine G1m
allotypes of intrathecally synthesized antibodies against measles, rubella and VZV. The same procedure was used to determine the G1m allotypes
of intrathecally synthesized antibodies against VZV in G1m1/G1m3 heterozygous controls with VZV meningoencephalitis. The intrathecal synthesis
of IgG1 of the G1m1 allotype alone was compared to that of IgG1 of both allotypes using Binomial test.
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hypothesized that GM genes could cause conformational
changes in the antigen-binding site of the immunoglobu-
lin variable regions,17 or that the genetic variants are
inherited together with polymorphisms in the variable
region genes.12 Any allotype-associated difference in the
variable region of the IgG1 molecule could influence
the affinity for a putative antigen and possibly explain the
observed G1m1 selection to the CSF in MS. The present
results argue against this possibility. Here, we demon-
strate a strong dominance of the G1m1 allotype in
intrathecally synthesized antibodies against measles,
rubella, and VZV. This suggests that G1m1 positive plas-
mablasts are selected to the CSF of MS patients indepen-
dently of their target antigen.
Several antigen-independent mechanisms explaining the
selection of G1m1 positive B cells are conceivable. Prefer-
ential interactions between Fc receptors and the G1m
allotypes have been suggested.18 Additionally, G1m allo-
type combinations have been shown to influence the
































































































































































Figure 2. Anti-viral antibodies of the G1m1 allotype are enriched in cerebrospinal fluid (CSF) of MS compared to serum, and compared to CSF
and serum of controls with varicella zoster virus meningoencephalitis (VZV-ME). (A) Measles-, rubella-, and VZV-specific G1m3 and G1m1
antibodies were quantified in paired serum and CSF samples of MS patients using ELISA, and the CSF:serum ratios were estimated. The bars
depict the median values. Comparisons were made using the Wilcoxon signed-rank test. Exceptions displaying G1m3 usage according to
isoelectric focusing and affinity blotting are marked in red. (B) VZV-specific G1m3 and G1m1 antibodies were quantified in paired serum and CSF
samples of VZV-ME controls using ELISA, and the CSF:serum ratios were estimated. The bars depict the median values. Comparisons were made
using the Wilcoxon signed-rank test. (C) G1m1/G1m3 ratios of VZV-specific antibodies in MS and VZV-ME samples of CSF and serum. The bars
correspond to the median values. Statistical significance was established using Kruskal-Wallis test on all groups, Wilcoxon signed-rank test
comparing patient CSF and serum, and Mann-Whitney U test comparing patients and controls.
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possibility is the existence of an inflammatory microenvi-
ronment within meningeal B-cell follicles or deep cervical
lymph nodes encouraging survival and/or differentiation
of G1m1 B cells in favor of G1m3. Such mechanisms
could involve the effect of cytokines on regulatory
elements upstream of the IGHG switch regions.9 Finally,
B-cell adhesion molecules are essential for maintaining
interactions with T follicular helper cells, and changes in
T-B adhesiveness can alter B-cell selection for clonal
expansion.20
The intrathecal polyspecific anti-viral immune
response is detected in most MS patients, but rarely in
other neuroinflammatory diseases.6 These findings have
also been confirmed in OCB negative contexts21 and in
clinically isolated syndrome patients who subsequently
converted to MS.22 The presence of an intrathecal
humoral immune response against these viruses in MS is
a conundrum. Most MS patients included in our study
have been vaccinated during childhood against measles
and rubella viruses, which makes the presence of these
viruses within the CSF or CNS unlikely. In the absence
of viral antigens,23 it has been suggested that the mecha-
nism might involve a local bystander activation of B
cells against irrelevant specificities. The possibility of
virus-specific B cells being cross-reactive to a yet unde-
termined self-antigen is not disproven. It might seem
implausible, however, since the anti-viral fraction of
intrathecally synthesized antibodies is directed against
several different viruses and does not cross-react between
the viruses.4 Moreover, it would be relevant to investi-
gate both the IgG1 allotype restriction and the intrathe-
cal polyspecific anti-viral reaction in MS patients with
other genetic backgrounds, such as Asian/Mongoloid
populations, in which there has been a chromosomal
crossover, leading to another combination of IgG1 allo-
types in a proportion of the individuals. Here, we found
similar levels of intrathecal virus-specific antibodies as
previous studies.4,24,25 Thus, it is unlikely that selection
bias has influenced our results. Additionally, we found
concordant results with quantitative and qualitative
methods. In conclusion, preferential intrathecal G1m
allotype usage in MS is not dependent on antigen speci-
ficity, supporting that the intrathecal synthesis of virus-
specific IgG is maintained by the same mechanisms as
the main fractions of the OCB.
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Table S1. Validation of anti-G1m1 and anti-G1m3 anti-
body specificities in patients with multiple sclerosis (MS)
and other inflammatory neurological diseases (OIND).
Figure S1. Optical density (OD) in ELISA for individuals
predicted by mass spectrometry to carry the G1m1 allo-
type and/or the G1m3 allotype.
Figure S2. (A) Representative isoelectric focusing and
affinity blotting against measles, rubella and VZV in
G1m1/G1m3 heterozygous MS patients, determining
virus-specific intrathecal IgG1 synthesis. (B) Positive
virus-specific IgG1 findings using IEF and affinity blotting
in G1m1/G1m3 heterozygous MS patients, according to
virus specificity and number of different viruses. (C) Rep-
resentative isoelectric focusing and affinity blotting against
VZV in three G1m1/G1m3 heterozygous controls with
VZV meningoencephalitis (VZV-ME).
Figure S3. Representative IEF and affinity blotting at four
different exposure times.
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